This is in agreement with the findings that higher IFN-γ and TNF-α cytokine levels at the time of diagnosis and three months after treatment initiation are linked to a better response to immunotherapy and a longer OS in NSCLC [20]. The gene discussed is IFNG; the disease is non-small cell lung carcinoma.